Evidence map›Paper›PMID 37147936›Full record

ArticleProteomics. Clinical applications2023

Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer.

Mriga Dutt, Gunter Hartel, Renee S Richards, Alok K Shah, Ahmed Mohamed, Sophia Apostolidou, Aleksandra Gentry-Maharaj, Australian Ovarian Cancer Study Group, John D Hooper, Lewis C Perrin and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proteomics. Clinical applications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Mriga DuttQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Gunter HartelQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Renee S RichardsQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Alok K ShahQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Ahmed MohamedQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Sophia ApostolidouMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Aleksandra Gentry-MaharajMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Australian Ovarian Cancer Study Group
John D HooperMater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
Lewis C PerrinMater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
Usha MenonMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Michelle M HillQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
QIMR Berghofer Medical Research Institute · AUTranslational Research Institute · AUMRC Clinical Trials Unit at UCL · GBThe University of Queensland · AU

Funding

Cancer Research UK C1479/A2884Department of HealthMedical Research Council G0801228Medical Research Council G9901012Medical Research Council MC_UU_00004/01
6 · The paper itself

Abstract

purposeThis study aimed to identify serum glycoprotein biomarkers for early detection of high-grade serous ovarian cancer (HGSOC), the most common and aggressive histotype of ovarian cancer. EXPERIMENTAL

designThe glycoproteomics pipeline lectin magnetic bead array (LeMBA)-mass spectrometry (MS) was used in age-matched case-control serum samples. Clinical samples collected at diagnosis were divided into discovery (n = 30) and validation (n = 98) sets. We also analysed a set of preclinical sera (n = 30) collected prior to HGSOC diagnosis in the UK Collaborative Trial of Ovarian Cancer Screening.

resultsA 7-lectin LeMBA-MS/MS discovery screen shortlisted 59 candidate proteins and three lectins. Validation analysis using 3-lectin LeMBA-multiple reaction monitoring (MRM) confirmed elevated A1AT, AACT, CO9, HPT and ITIH3 and reduced A2MG, ALS, IBP3 and PON1 glycoforms in HGSOC. The best performing multimarker signature had 87.7% area under the receiver operating curve, 90.7% specificity and 70.4% sensitivity for distinguishing HGSOC from benign and healthy groups. In the preclinical set, CO9, ITIH3 and A2MG glycoforms were altered in samples collected 11.1 ± 5.1 months prior to HGSOC diagnosis, suggesting potential for early detection. CONCLUSIONS AND CLINICAL RELEVANCE: Our findings provide evidence of candidate early HGSOC serum glycoprotein biomarkers, laying the foundation for further study in larger cohorts.

Indexed as

Cystadenocarcinoma, SerousOvarian NeoplasmsAryldialkylphosphataseBiomarkers, TumorFemaleGlycoproteinsHumansLectinsTandem Mass SpectrometryAryldialkylphosphataseBiomarkers, TumorGlycoproteinsLectinsPON1 protein, humanhigh grade serous ovarian cancerlectin magnetic bead array (LeMBA)mass spectrometryovarian cancer screeningserum glycoprotein biomarker

Identifiers

PMID37147936
PMCPMC7615076
OpenAlexW4372330943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.